MarkosWebWeb intelligence for the agentic economy

Diapin Therapeutics

Active

Novel Therapies for Cardiovascular and Metabolic Diseases

diapin.comAI readiness report

What it does

Diapin Therapeutics is a health and lifetech company focused on developing novel therapies for cardiovascular and metabolic diseases. The company’s mission centers on advancing innovative treatments to address critical unmet medical needs in these areas. Its key products include DT678, a best-in-class anti-platelet therapy designed to prevent stroke and heart attacks in cardiovascular disease patients, and DT109, a peptide targeting metabolic conditions such as non-alcoholic fatty liver disease (NAFLD), metabolic-associated steatohepatitis (MASH), and atherosclerosis. Both assets originated from academic research and are progressing through clinical and preclinical development stages. Diapin Therapeutics contributes to medical innovation by translating cutting-edge scientific discoveries into promising therapeutic candidates aimed at improving patient outcomes in complex chronic diseases.

Next to it in Healthcare and bio · Cardiovascular and metabolic therapeutics

  • Adipo TherapeuticsPlug and Play PnP 2026

    Adipo Therapeutic is a biotechnology company that is developing a novel asset for the treatment of obesity by increasing energy expenditure via mitochondria biogenesis and activation in white adipose tissue (fat browning).

  • Bahto BiosciencesPlug and Play PnP 2026

    Bahto Biosciences develops non-opioid small-molecule therapeutics for painful peripheral neuropathy, a condition with limited effective treatment options that afflicts more than 19 million Americans.

  • Cryton BiosciencesPlug and Play PnP 2026

    Cryton Biosciences is developing a first-in-class dual-action drug that restores mitochondrial function in immune AND cancer cells resulting in tumor death.

  • RNARevivePlug and Play PnP 2026

    RNARevive is developing a next-generation RNA platform that enables long-lasting, low-dose protein therapeutics. Our lead candidates tackle the anti-aging and longevity space, targeting osteoporosis, age-related macular degeneration (AMD), and liver diseases.

  • ReRxBerkeley SkyDeck SkyDeck Batch 17

    ReRx Therapeutics

  • FinalDoseY Combinator X26

    Programmable DNA drug destroying all cancers, unlocking 80% of targets

  • Scioto BiosciencesPlug and Play PnP 2025

    Scioto is a preclinical stage company developing innovative therapies devoted to having a transformative impact.

  • Eris BiotechY Combinator W24

    Our drugs engage the immune system to fight tumors